Janssen, the pharmaceutical company of Johnson & Johnson, focuses on some of the most devastating diseases and the most complex medical challenges of our time, across the following five therapeutic areas: Cardiovascular and Metabolism, Neuroscience, Immunology, Oncology and hematology, and Infectious Diseases and Vaccines.
Janssen employs nearly 40,000 people in more than 150 countries around the world. We work to bring innovative treatments for serious unmet medical needs.
Contact
41 Mohamed Tawfiq Diab St (off Makram Ebiad St.)
Nasr City, Cairo
Tel: 02-22707669/70/25
Ramez Mohsen, managing director at Janssen for Egypt, Jordan, Libya & Sudan, highlights how the company is driving real access to treatments in Egypt through collaboration with various stakeholders. He…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years –…
Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do…
General manager of MEA, Khaled Elrefae, explains how Ipsen has strengthened its footprint in the region over the past two years – starting in the UAE and expanding into Saudi…
See our Cookie Privacy Policy Here
